Document is current
Any future updates will be listed below
-
Authors
Kocher, Hemant M. https://orcid.org/0000-0001-6771-1905
Basu, Bristi https://orcid.org/0000-0002-3562-2868
Froeling, Fieke E. M.
Sarker, Debashis
Slater, Sarah
Carlin, Dominic https://orcid.org/0000-0002-1783-412X
deSouza, Nandita M.
De Paepe, Katja N.
Goulart, Michelle R. https://orcid.org/0000-0001-8333-3908
Hughes, Christine
Imrali, Ahmet https://orcid.org/0000-0003-3661-9932
Roberts, Rhiannon
Pawula, Maria
Houghton, Richard
Lawrence, Cheryl
Yogeswaran, Yathushan https://orcid.org/0000-0002-5220-9135
Mousa, Kelly
Coetzee, Carike https://orcid.org/0000-0002-4933-1279
Sasieni, Peter https://orcid.org/0000-0003-1509-8744
Prendergast, Aaron https://orcid.org/0000-0002-9668-6689
Propper, David J. https://orcid.org/0000-0002-4274-5460
- License Information
-
More Information
Article History
Received: 6 July 2020
Accepted: 2 September 2020
First Online: 24 September 2020
Competing interests
: H.M.K. received research grant for conducting this trial (Celgene: institutional) and educational grant support for attending or organizing conferences (Celgene, Baxalta, Mylan, Medtronic, Oncosil: institutional) which are unrelated to this work. S.S. has consultancy with Eisai UK which have no direct relation to this work. B.B. has consulting role (Eisai Europe Limited, Roche, GenMab, Baxter Innovations, Celgene, Biocompatibles Ltd, Nordic Pharma SAS: all payments to institution), is on speaker’s bureau (Eisai Europe Limited), received research funding (Celgene: investigator initiated trial), and has educational grant support for attending conferences (Bayer, Celgene), all of which have no direct relation to this work. D.S. is on advisory boards for Eisai, Novartis, Ipsen, and Surface Oncology; speaker honoraria from Astra Zeneca, Eisai, M.S.D., and Bayer; travel sponsorship from Eisai, Ipsen, and MiNA Therapeutics, all of which have no direct relation to this work. The remaining authors declare no competing interests.
